Clinical trials: Peptic Ulcers
Reflux Esophagitis
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
- Trial name
- NCT05813561
- Testing
- DWP14012
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Peptic Ulcer Disease
Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately
The purpose of this study is to investigate whether treatment with a combination capsule of Esomeprazole 40 mg and Aspirin (ASA) 325 mg is bioequivalent (i.e.has the same effect within the body) as these medications taken…
- Trial name
- NCT00998075
- Testing
- Esomeprazole/ASA Fixed Combination, Esomeprazole - Nexium, ASA
- Where
- Canada
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gastric Ulcer
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer
- Trial name
- NCT07730138
- Testing
- DWP14012 40mg (Fexuprazan), Lansoprazole 30mg
- Where
- 2 sites in Indonesia, South Korea
- Volunteers
- 384 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Peptic Ulcer
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of DWP14012 20 mg.
- Trial name
- NCT04784910
- Testing
- DWP14012 20mg, Lansoprazole 15 mg
- Where
- South Korea
- Volunteers
- 423 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastric Ulcers, Duodenal Ulcers
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
The purpose of this study is to evaluate the safety of TAK-438, once daily (QD), during long-term concomitant non-steroidal anti-inflammatory drug (NSAID) therapy in patients with a history of gastric or duodenal ulcer who…
- Trial name
- NCT01456260
- Testing
- TAK-438, Lansoprazole
- Where
- 97 sites in Japan
- Volunteers
- 406 people
- Sponsor
- Takeda